💥🇺🇸#VRTX Vertex Pharmaceuticals stock price target raised to $305 from $281 at J.P. Morgan💥🇺🇸#SGEN Seattle Genetics stock price target raised to $179 from $150 at J.P. Morgan💥🇺🇸#LRCX Lam Research stock price target raised to $435 from $270 at B. Riley FBR⚠️🇺🇸#BIIB Biogen stock price target cut to $272 from $293 at J.P. Morgan💥🇺🇸#PYPD POLYPID started at OUTPERFORM with $23 stock price target at Raymond James💥🇺🇸#EXK ENDEAVOUR SILVER started at BUY with $4.75 stock price target at B. Riley FBR⚠️🇺🇸#FNHC FEDNAT downgraded to OUTPERFORM from STRONG BUY at Raymond James⚠️🇺🇸#NDAQ NASDAQ downgraded to MARKET PERFORM from OUTPERFORM at Raymond James
Акции США
VRTX
Рост целевой цены акций Vertex Pharmaceuticals до $305
J.P. Morgan повысил целевую цену акций Vertex Pharmaceuticals до $305.
Контекст по активу
Vertex Pharmaceuticals Incorpora (VRTX). Бумага относится к сектору "Здравоохранение". Последняя цена: 383,12 USD. Текущая дневная динамика: 0%. Актив есть в портфелях 117 пользователей FinPlan. Капитализация около 97,41 млрд USD.